FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W165010227> ?p ?o ?g. }

• W165010227 endingPage "23" @default.
• W165010227 startingPage "15" @default.
• W165010227 abstract "To evaluate the safety and physiologic response of inhaled nitric oxide (NO) in patients with acute respiratory distress syndrome (ARDS). In addition, the effect of various doses of inhaled NO on clinical outcome parameters was assessed.Prospective, multicenter, randomized, double-blind, placebo-controlled study.Intensive care units of 30 academic, teaching, and community hospitals in the United States.Patients with ARDS, as defined by the American-European Consensus Conference, were enrolled into the study if the onset of disease was within 72 hrs of randomization.Patients were randomized to receive placebo (nitrogen gas) or inhaled NO at concentrations of 1.25, 5, 20, 40, or 80 ppm.Acute increases in PaO2, decreases in mean pulmonary arterial pressure, intensity of mechanical ventilation, and oxygenation index were examined. Clinical outcomes examined were the dose effects of inhaled NO on mortality, the number of days alive and off mechanical ventilation, and the number of days alive after meeting oxygenation criteria for extubation. A total of 177 patients were enrolled over a 14-month period. An acute response to treatment gas, defined as a PaO2 increase > or =20%, was seen in 60% of the patients receiving inhaled NO with no significant differences between dose groups. Twenty-four percent of placebo patients also had an acute response to treatment gas during the first 4 hrs. The initial increase in oxygenation translated into a reduction in the FIO2 over the first day and in the intensity of mechanical ventilation over the first 4 days of treatment, as measured by the oxygenation index. There were no differences among the pooled inhaled NO groups and placebo with respect to mortality rate, the number of days alive and off mechanical ventilation, or the number of days alive after meeting oxygenation criteria for extubation. However, patients receiving 5 ppm inhaled NO showed an improvement in these parameters. In this dose group, the percentage of patients alive and off mechanical ventilation at day 28 (a post hoc analysis) was higher (62% vs. 44%) than the placebo group. There was no apparent difference in the number or type of adverse events reported among those patients receiving inhaled NO compared with placebo. Four patients had methemoglobin concentrations >5%. The mean inspired nitrogen dioxide concentration in inhaled NO patients was 1.5 ppm.From this placebo-controlled study, inhaled NO appears to be well tolerated in the population of ARDS patients studied. With mechanical ventilation held constant, inhaled NO is associated with a significant improvement in oxygenation compared with placebo over the first 4 hrs of treatment. An improvement in oxygenation index was observed over the first 4 days. Larger phase III studies are needed to ascertain if these acute physiologic improvements can lead to altered clinical outcome." @default.
• W165010227 created "2016-06-24" @default.
• W165010227 creator A5009003396 @default.
• W165010227 creator A5018057407 @default.
• W165010227 creator A5018214563 @default.
• W165010227 creator A5031949625 @default.
• W165010227 creator A5056013020 @default.
• W165010227 creator A5057960598 @default.
• W165010227 creator A5064656041 @default.
• W165010227 creator A5068644121 @default.
• W165010227 creator A5084807445 @default.
• W165010227 date "1998-01-01" @default.
• W165010227 modified "2023-09-27" @default.
• W165010227 title "Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome" @default.
• W165010227 cites W150631554 @default.
• W165010227 cites W1964068478 @default.
• W165010227 cites W1968236889 @default.
• W165010227 cites W1983761587 @default.
• W165010227 cites W1985864082 @default.
• W165010227 cites W2008784714 @default.
• W165010227 cites W2011306732 @default.
• W165010227 cites W2037903706 @default.
• W165010227 cites W2042322531 @default.
• W165010227 cites W2068600461 @default.
• W165010227 cites W2073590270 @default.
• W165010227 cites W2081607964 @default.
• W165010227 cites W2091305912 @default.
• W165010227 cites W2092145002 @default.
• W165010227 cites W2093216413 @default.
• W165010227 cites W2126624423 @default.
• W165010227 cites W2128139551 @default.
• W165010227 cites W2140036859 @default.
• W165010227 cites W2154517401 @default.
• W165010227 cites W2161328469 @default.
• W165010227 cites W2324162185 @default.
• W165010227 cites W2034291309 @default.
• W165010227 doi "https://doi.org/10.1097/00003246-199801000-00011" @default.
• W165010227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9428538" @default.
• W165010227 hasPublicationYear "1998" @default.
• W165010227 type Work @default.
• W165010227 sameAs 165010227 @default.
• W165010227 citedByCount "697" @default.
• W165010227 countsByYear W1650102272012 @default.
• W165010227 countsByYear W1650102272013 @default.
• W165010227 countsByYear W1650102272014 @default.
• W165010227 countsByYear W1650102272015 @default.
• W165010227 countsByYear W1650102272016 @default.
• W165010227 countsByYear W1650102272017 @default.
• W165010227 countsByYear W1650102272018 @default.
• W165010227 countsByYear W1650102272019 @default.
• W165010227 countsByYear W1650102272020 @default.
• W165010227 countsByYear W1650102272021 @default.
• W165010227 countsByYear W1650102272022 @default.
• W165010227 countsByYear W1650102272023 @default.
• W165010227 crossrefType "journal-article" @default.
• W165010227 hasAuthorship W165010227A5009003396 @default.
• W165010227 hasAuthorship W165010227A5018057407 @default.
• W165010227 hasAuthorship W165010227A5018214563 @default.
• W165010227 hasAuthorship W165010227A5031949625 @default.
• W165010227 hasAuthorship W165010227A5056013020 @default.
• W165010227 hasAuthorship W165010227A5057960598 @default.
• W165010227 hasAuthorship W165010227A5064656041 @default.
• W165010227 hasAuthorship W165010227A5068644121 @default.
• W165010227 hasAuthorship W165010227A5084807445 @default.
• W165010227 hasConcept C126322002 @default.
• W165010227 hasConcept C142724271 @default.
• W165010227 hasConcept C168563851 @default.
• W165010227 hasConcept C177713679 @default.
• W165010227 hasConcept C204787440 @default.
• W165010227 hasConcept C27081682 @default.
• W165010227 hasConcept C2776348555 @default.
• W165010227 hasConcept C2777080012 @default.
• W165010227 hasConcept C2777714996 @default.
• W165010227 hasConcept C2780826366 @default.
• W165010227 hasConcept C2987404301 @default.
• W165010227 hasConcept C42219234 @default.
• W165010227 hasConcept C70289976 @default.
• W165010227 hasConcept C71924100 @default.
• W165010227 hasConceptScore W165010227C126322002 @default.
• W165010227 hasConceptScore W165010227C142724271 @default.
• W165010227 hasConceptScore W165010227C168563851 @default.
• W165010227 hasConceptScore W165010227C177713679 @default.
• W165010227 hasConceptScore W165010227C204787440 @default.
• W165010227 hasConceptScore W165010227C27081682 @default.
• W165010227 hasConceptScore W165010227C2776348555 @default.
• W165010227 hasConceptScore W165010227C2777080012 @default.
• W165010227 hasConceptScore W165010227C2777714996 @default.
• W165010227 hasConceptScore W165010227C2780826366 @default.
• W165010227 hasConceptScore W165010227C2987404301 @default.
• W165010227 hasConceptScore W165010227C42219234 @default.
• W165010227 hasConceptScore W165010227C70289976 @default.
• W165010227 hasConceptScore W165010227C71924100 @default.
• W165010227 hasIssue "1" @default.
• W165010227 hasLocation W1650102271 @default.
• W165010227 hasLocation W1650102272 @default.
• W165010227 hasOpenAccess W165010227 @default.
• W165010227 hasPrimaryLocation W1650102271 @default.
• W165010227 hasRelatedWork W165010227 @default.

• next